icosapent ethyl / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 26 Diseases   6 Trials   6 Trials   4342 News 


«12...2728293031323334353637...5051»
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    [VIRTUAL] Scenario Analyses of Lifetime Cost-effectiveness of Icosapent Ethyl in REDUCE-IT () -  May 13, 2020 - Abstract #QCOR2020QCOR_44;    
    IPE 4 g/day provides robust CV benefits in statin-treated patients with DM, with large relative and absolute risk reductions in both first and total CV events. Icosapent ethyl at a cost of $4.16/day was shown to be cost-effective at willingness-to-pay thresholds of $50,000 per QALY, and a dominant strategy in all post trial persistence-of-IE-effect scenarios.
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Clinical, Review, Journal:  Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. (Pubmed Central) -  May 7, 2020   
    A sub-analysis of ODYSSEY OUTCOMES examined the effect of alirocumab on lipoprotein(a) lowering for reducing CVD risk...Lastly, post hoc analyses from DECLARE-TIMI 58 evaluated the efficacy of dapagliflozin among patients with type 2 diabetes mellitus and heart failure or peripheral artery disease. These trials hold future promise for novel agents aimed at reducing CVD burden among high-risk patients who continue to experience CVD events despite treatment with currently available guideline-directed therapy.
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT () -  May 6, 2020 - Abstract #AMCP2020AMCP_105;    
    In this combined patient-level and simulation cost-effectiveness analysis, icosapent ethyl at $4.16 a day in high CV risk patients shows exceptional benefit, with CV event reduction plus cost savings in-trial and over patients’ lifetime in the majority of simulations. Sponsorship: Amarin Corporation
  • ||||||||||  icosapent ethyl / Generic mfg.
    Trial initiation date:  PREPARE: PRevention Using EPA Against coloREctal Cancer (clinicaltrials.gov) -  Apr 30, 2020   
    P1/2,  N=80, Not yet recruiting, 
    Sponsorship: Amarin Corporation Initiation date: Mar 2020 --> Jun 2020
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Retrospective data, Review, Journal:  Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) -  Apr 30, 2020   
    A recent randomized controlled trial (RCT), the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT), reported that high-dose marine omega-3 fatty acids (OM3) significantly reduce cardiovascular disease (CVD) outcomes, yet the mechanisms responsible for this benefit remain unknown...High-dose OM3 significantly slowed the progression of atherosclerosis (standardized mean difference -1.97, 95% confidence interval -3.01, -0.94, p < 0.001). The results indicate that anti-atherosclerotic effect of high-dose OM3 is one potential mechanism in reducing CVD outcomes demonstrated in the REDUCE-IT trial.
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Icosapent Ethyl. (Twitter) -  Apr 29, 2020   
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Add Vascepa (Twitter) -  Apr 27, 2020   
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Clinical, Journal:  Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014. (Pubmed Central) -  Apr 25, 2020   
    Over 12 million Americans are treated with a statin and have TG levels ≥ 150 mg/dl. Interventions such as icosapent ethyl that have been shown to reduce ASCVD event risk in this elevated TG population with type 2 diabetes or established ASCVD can provide substantial clinical benefit for these patients.
  • ||||||||||  Vascepa (icosapent ethyl) / Amarin, HLS Therap
    Journal:  Cardiovascular risk reduction with icosapent ethyl. (Pubmed Central) -  Apr 15, 2020   
    Icosapent ethyl was rigorously shown to decrease residual risk for cardiovascular events, though the benefits seen were likely because of mechanisms beyond mere triglyceride lowering. Clinical application of icosapent ethyl in this cohort of patients with residual risk is urgently needed.